Solubilizing Excipients in Oral and Injectable Formulations

Pharmaceutical Research

Volumn 21, Issue 2, 2004, Pages 201-230

  Strickley, Robert G ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

Excipients; Oral formulations; Parenteral formulations; Solubilization

Indexed keywords

AMPRENAVIR; BEXAROTENE; CALCITRIOL; CLOFAZIMINE; CYCLODEXTRIN; CYCLOSPORIN A; DIGOXIN; DONNATAL; DOXERCALCIFEROL; DRONABINOL; DUTASTERIDE; ETOPOSIDE; EXCIPIENT; ISOTRETINOIN; ITRACONAZOLE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; LORATADINE; NIFEDIPINE; NIMODIPINE; NONIONIC SURFACTANT; ORGANIC SOLVENT; PHENOBARBITAL; PHOSPHOLIPID; PROGESTERONE; RAPAMYCIN; RESPERDAL; RETINOIC ACID; RISPERIDONE; RITONAVIR; SAQUINAVIR; UNINDEXED DRUG; VALPROIC ACID;

COMPLEX FORMATION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; EXCIPIENT COMPATIBILITY; MICELLE; MICROEMULSION; PH MEASUREMENT; PRIORITY JOURNAL; REVIEW; TEMPERATURE DEPENDENCE;

ADMINISTRATION, ORAL; CHEMISTRY, PHARMACEUTICAL; CYCLODEXTRINS; DRUG CARRIERS; EMULSIONS; EXCIPIENTS; HYDROGEN-ION CONCENTRATION; INJECTIONS, INTRAVENOUS; PHARMACEUTICAL PREPARATIONS; PHOSPHOLIPIDS; SOLUBILITY; SOLVENTS; SURFACE-ACTIVE AGENTS; TECHNOLOGY, PHARMACEUTICAL;

EID: 1242337285     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000016235.32639.23     Document Type: Review

References (90)

1. R. Liu (ed.). Water-Insoluble Drug Formulation, Interpharm Press, Denver, Colorado, 2000.
2. Physician's Desk Reference, 57rd ed., Medical Economics Company, Inc., Montvale, NJ, 2003.
3. Web sites: www.rxlist.com, www.fda.gov/cder, www.croda.com/ pharma/index.htm, www.sasol.com, www.gattefosse.com/pharma/ pharma.htm, www.basf.de/pharma.com, www.cydexinc.com, www. atrixlabs.com, www.accessdata.fda.gov/scripts/cder/iig/index.cfm.
4. A. L. Trissel. Handbook on Injectable Drugs, 11th ed., American Society of Health-System Pharmacists, Inc., Bethesda, MD, 2001.
5. Y-C. J. Wang and R. R. Kowal. Review of excipients and pH's for parenteral products used in the United States. J. Parent. Sci. Technol. 34:452-462 (1980).
6. S. Sweetana and M. J. Akers. Solubility principles and practices for parenteral dosage form development. J. Parent. Sci. Technol. 50:330-342 (1996).
7. M. F. Powell, T. Nguyen, and L. Baloian. Compendium of excipients for parenteral formulations. J. Parent. Sci. Technol. 52:238-311 (1998).
8. R. G. Strickley. Parenteral formulations of small molecule therapeutics marketed in the United States (1999) - Part I. J. Parent. Sci. Technol. 53:324-349 (1999).
9. R. G. Strickley. Parenteral formulations of small molecule therapeutics marketed in the United States (1999) - Part II. J. Parent. Sci. Technol. 54:69-96 (2000).
10. R. G. Strickley. Parenteral formulations of small molecule therapeutics marketed in the United States (1999) - Part II. J. Parent. Sci. Technol. 54:152-169 (2000).
11. S. Yoshioka and V. Stella. Stability of Drugs and Dosage Forms, Kluwer Academic/Plenum Publishers, New York, 2000.
12. J. S Trivedi and M. L. Wells. Solubilization using cosolvent approach. In R. Liu (ed.), Water-Insoluble Drug Formulation, Interpharm Press, Denver, Colorado, 2000, pp. 141-168.
13. R. A. Rajexski and V. J. Stella. Pharmaceutical applications of cyclodextrins. II. In vivo drug delivery. J. Pharm. Sci. 85:1142-1169 (1996).
14. R. G. Strickley and B. D. Anderson. Solubilization and stabilization of an anti-HIV thiocarbamate, NSC 629243, for parenteral delivery using extemporaneous emulsions. Pharm. Res. 10:1076-1082 (1993).
15. S. E. Tabibi and S. L. Gupta. Soft gelatin capsules development. In R. Liu (ed.), Water-Insoluble Drug Formulation, Interpharm Press, Denver, Colorado, 2000, pp. 609-633.
16. Shionogi Qualicaps, Inc. Web site: http://www.qualicaps.com/ shionogi/Capsules/Products.html.
17. E. T. Cole, R. A. Scott, A. L. Connor, I. R. Widding, H-U Petereit. C. Schminke, T. Beckert, and C. Cade. Enteric coated HPMC capsules designed to achieve intestinal targeting. Int. J. Pharm. 231:83-95 (2002).
18. CTP Plasro Web site: www.plasro.com.
19. R. Pidgeon. PVOH developments offer new possibilities. Packaging Magazine June 26:3 (2003).
20. Arkopharma Laboratories Pharmaceutiques Web site: www. arkopharma.com/english/IndexProduits.html.
21. thed., Medical Economics Company, Inc., Montvale, NJ, 2000.
22. D. Law, S. L. Krill, E. A. Schmitt, J. J. Fort, Y. Qiu, W. Wang, and R. R. Porter. Physicochemical considerations in the preparation of amorphous ritonavir-poly(ethylene glycol) 8000 solid dispersions. J. Pharm. Sci. 90:1015-1025 (2001).
23. S. Budavari (ed.). The Merck Index, 13th ed., Merck Research Laboratories Division of Merck & Co., Inc., Whitehouse Station NJ, 2001.
24. J. Alsenz, H. Steffen, and R. Alex. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in caco-2 cell monolayers. Pharm. Res. 15:423-428 (1998).
25. V. Stella, J. Haslam, N. Yata, H. Okada, and S. Lindebaum. Enhancement of bioavailability of a hydrophobic amine antimalarial by formulation with oleic acid in a soft gelatin capsule. J. Pharm. Sci. 67:1375-1377 (1978).
26. R. C. Rowe, P. J. Sheskey, and P. J. Weller. Handbook of Pharmaceutical Excipients, Fourth Edition, Pharmaceutical Press, London, United Kingdom, and the American Pharmaceutical Association, Washington, DC, 2003.
27. Product literature. Gattefosse Corp., 372 Kinderkamack Road, Westwood, NJ 07675.
28. N. H. Shah, M. T. Carvajal, C. I. Patel, M. H. Infeld, and A. W. Malick. Self-emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. Int. J. Pharm. 106:15-23 (1994).
29. Physician's Desk Reference, 51st ed., Medical Economics Company, Inc., Montvale, NJ, 1997.
30. T. M. Abu. Serajuddin. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 88:1058-1066 (1999).
31. Pharmacy Today. An Official Publication of the American Pharmaceutical Association 5:10 (1999).
32. J. D. Cawley and M. H. Stern. Water-Soluble Tocopherol Derivatives, U.S. Patent No. 2,680,749 (1954).
33. S. H-W. Wu and W. K. Hopkins. Characteristics of D-α-tocopheryl PEG 1000 succinate for applications as an absorption enhancer in drug delivery systems. Pharm. Tech. 23:44-58 (1999).
34. L. Yu, A. Bridgers, J. Polli, A. Vickers, S. Long, A. Roy, R. Winnike, and M. Coffin. Vitamin-E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm. Res. 16: 1812-1817 (1999).
35. S. Tenjarla. Microemulsions: an overview and pharmaceutical applications. Crit. Rev. Ther. Drug Carrier Syst. 16:461-521 (1999).
36. T. Loftsson and M. E. Brewster. Pharmaceutical applications of cyclodextrins. I. Drug solubilization and stabilization. J. Pharm. Sci. 85:1017-1024 (1996).
37. T. Irie and K. Uekama. Pharmaceutical applications of cyclodextrins. III. Toxicology issues and safety evaluation. J. Pharm. Sci. 86:147-162 (1997).
38. G. Mosher and D. Thompson. Complexation and cyclodextrins. In J. Swarbrick and J. C. Boylan (eds.), Encyclopedia of Pharmaceutical Technology, 2000, Vol. 19, Suppl. 2, pp. 49-88.
39. D. Thompson. Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals. Crit. Rev. Ther. Drug Carrier Syst. 14:1-104 (1997).
40. W-Q. Tong. Applications of complexation in the formulation of insoluble compounds. In R. Liu (ed.), Water-Insoluble Drug Formulation, Interpharm Press, Denver, Colorado, 2000, pp. 111-140.
41. M. J. Akers. Excipient-drug interactions in parenteral formulations. J. Pharm. Sci. 91:2283-2306 (2002).
42. J. Napaporn, M. Thomas, K. A. Svetic, Z. Shahrokh, and G. A. Brazeau. Assessment of the myotoxicity of pharmaceutical buffers using an in vitro muscle model: Effect of pH, capacity, tonicity, and buffer type. Pharm. Dev. Tech. 5:123-130 (2000).
43. Y-C. Lee, P. D. Zocharski, and B. Samas. An intravenous formulation decision tree for discovery compound formulation development. Intl. J. Pharm 253:111-119 (2003).
44. G. A. Brazeau, B. Cooper, K. A. Svetic, C. L. Smith, and P. Gupta. Current perspectives on pain upon injection of drugs. J. Pharm. Sci. 87:667-677 (1998).
45. K. W. Reed and S. H. Yalkowsky. Lysis of human red blood cells in the presence of various cosolvents. J. Parent. Sci. Technol. 38:64-69 (1985).
46. K. W. Reed and S. H. Yalkowsky. Lysis of human red blood cells. II. The effect of differing NaCl concentrations. J. Parent. Sci. Technol. 40:88-95 (1986).
47. J. F. Krzyaniak, D. M. Raymond, and S. H. Yalkowsky. Lysis of human red blood cells 1: effect of contact time on water induced hemolysis. J. Pharm. Sci. Tech. 50:223-226 (1996).
48. J. F. Krzyaniak, D. M. Raymond, and S. H. Yalkowsky. Lysis of human red blood cells 2: effect of contact time on cosolvent induced hemolysis. Int. J. Pharm. 152:193-200 (1997).
49. R. C-C. Fu, D. M. Lidgate, J. L. Whatley, and T. McCullough. The biocompatibility of parenteral vehicles-in vitro/in vivo screening comparison and the effect of excipients on hemolysis. J. Parent. Sci. Technol. 41:164-168 (1987).
50. P. Montaguti, E. Melloni, and E. Cavalletti. Acute intravenous toxicity of dimethyl sulfoxide, polyethylene glycol 400, dimethylformamide, absolute ethanol, and benzyl alcohol in inbred mouse strains. Arzneim.-Forsch/Drug Res. 44:566-570 (1994).
51. G. A. Brazeau and H-L. Fung. Physicochemical properties of binary organic cosolvent-water mixtures and their relationships to muscle damage following intramuscular injection. J. Parent. Sci. Technol. 43:144-149 (1989).
52. G. A. Brazeau and H-L. Fung. Use of an in vitro model for the assessment of muscle damage from intramuscular injections: in vitro-in vivo correlation and predictability with mixed cosolvent systems. Pharm. Res. 6:766-771 (1989).
53. G. A. Brazeau and H-L. Fung. Effect of organic solvent-induced skeletal muscle damage on the bioavailability of intramuscular [14C] diazepam. J. Pharm. Sci. 79:773-777 (1990).
54. M. Radwan. In vivo screening model for excipients and vehicles used in subcutaneous injections. Drug Dev. Ind. Pharm. 20:2753-2762 (1994).
55. R. Dunn. Controlled drug delivery using in-situ gelled biodegradable polymer solutions. American Association of Pharmaceutical Scientists National Meeting, Denver, CO (2001).
56. R. Dunn. Application of the ATRIGEL® implant drug delivery technology for patient-friendly, cost-effective product development. Drug Delivery Tech 3:38-44 (2003).
57. BASF Corporation Web site: www.basf.de/pharma and wwvv. pharma-solutions.basf.com/pdf/pharma/excipients/ME151e_ Solutol_HS15.pdf.
58. Personal communication. Brendan O'Leary, BASF Corporation. (2003).
59. R. G. Strickley, L. Liu, and P. Lapresca. Preclinical parenteral and oral formulations of water insoluble molecules. ISSX Meeting, Nashville, TN (USA) Abstract # 291 (1999).
60. R. Liu and N. Sadrzadeh. Micellization and drug solubility enhancement. In R. Liu (ed.), Water-Insoluble Drug Formulation, Interpharm Press, Denver, Colorado, 2000, pp. 213-277.
61. P. K. Gupta and J. B. Cannon. Emulsions and microemulsions for drug solubilization and delivery. In R. Liu (ed.), Water-Insoluble Drug Formulation, Interpharm Press, Denver, Colorado, 2000, pp. 169-211.
62. D. Thompson and D.M.V. Chaubai, Cyclodextrins (CDS) -excipients by definition, drug delivery systems by function (part I: injectable applications), Drug Deliv. 2:34-38 (2002).
63. Y. Kim, D. A. Oksanen, W. Massrfski, J. F. Blake, E. M. Duffy, and B. Chrunyx. Inclusion complexation of ziprasidone mesylate with β-cyclodextrin sulfobutylether. J. Pharm. Sci. 87:1560-1567 (1998).
64. "Captisol Wins in Regulatory Hurdle," Cyclopedia Quarterly 4(1), (2001), CyDex, Inc.
65. Personal communication, Gerold L Mosher, Ph.D. and Karl W. Strohmeier, CyDex, Inc. (2001).
66. A. Y. Tinwalla, B. L. Hoesterey, T-X. Xiang, K. Lim, and B. D. Anderson. Solubilization of thiazolobenzimidazole using a combination of pH adjustment and complexation with 2-hydroxypropyl-β-cyclodextrin. Pharm. Res. 10:1136-1143 (1993).
67. T-X. Xiang and B. D. Anderson. Stable supersaturated aqueous solutions of silatecan 7-t-butyldimethylsilyl-10-hydroxy-camptothecin via chemical conversion in the presence of a chemically modified β-cyclodextrin. Pharm. Res. 19:1215-1222 (2002).
68. S.P. Apte and S.O. Ugwu. A review and classification of emerging excipients in parenteral medications. Pharm. Tech. 27:3:46-60 (2003).
69. L. A. Felton and J. W. McGinity. Enteric film coating of soft gelatin capsules. Drug Deliv. Tech. 3:46-51 (2003).
70. J. S. Woo, C. H. Lee, C. K. Shim, and S-J Hwang. Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR-30031. Pharm. Res. 20:24-30 (2003).
71. F. Mottu, A. Laurent, D. A. Rüfenacht, and E. Doelker. Organic solvents for pharmaceutical parenterals and embolic liquids: a review of toxicity data. J. Parent. Sci. Tech. 54:456-469 (2000).
72. Gattefossé Corporation Web site: www.gattefosse.com/pharma/ products/transcup.
73. M-L Chen. Lipid based oral dosage forms - regulatory perspective. Am. Pharm. Rev. 5:30-35 (2002).
74. D. J. Hauss. Lipid-based systems for oral drug delivery: enhancing the bioavailability of poorly water-soluble drugs. Am. Pharm. Rev. 5:22-36 (2002).
75. W. C. Charman. Lipids, lipophilic drugs, and oral drug delivery -some emerging concepts. J. Pharm. Sci. 89:967-978 (2000).
76. R. Holm, C. J. H. Porter, A. Müllertz, H. G. Kristensen, and W. M. Charman. Structured triglyceride vehicles for oral delivery of halofantrine: examination of intestinal lymphatic transport and bioavailability in conscious rats. Pharm. Res. 19:1354-1361 (2002).
77. R. C. B. Gonzalez, J. Huwyler, I. Walter, R. Mountfield, and B. Bittner. Improved oral bioavailability of cyclosporin A in male Wistar rats comparison of a Solutol HS 15 containing self-dispersing formulation and a microsuspension. Intl. J. Pharm 245: 143-151 (2002).
78. Y. V. R. Prasad, S. P. Puthli, S. Eaimtrakarn, M. Ishida, Y. Yoshikawa, N. Shibata, and K. Takada. Enhanced intestinal absorption of vancomycin with Labrasol and D-α-tocopherol PEG 1000 succinate in rats. Intl. J. Pharm. 250:181-190 (2003).
79. Southern Biosystems, Inc., Web site: www.southernbiosystems. com.
80. Durect Corporation Web site: www.durect.com.
81. A. V. Kabanov, E. V. Batrakova, and D. W. Miller. Pluronic® blocks as modulators of drug efflux transporter activity in the blood-brain barrier. Adv. Drug. Del. Rev. 55:151-164 (2003).
82. E. D. Hugger, K. L. Audus, and R. T. Borchardt. Effects of polyethylene glycol on efflux transporters activity in Caco-2 cell monolayers. J. Pharm. Sci. 91:1980-1990 (2002).
83. E. D. Hugger, B. Novak, P. S. Burton, K. L. Audus, and R. T. Borchardt. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J. Pharm. Sci. 91:1991-2002 (2002).
84. R. T. Borchardt, R. M. Freidinger, T. K. Sawyer, and P. L. Smith (eds.). Integration of Pharmaceutical Discovery and Development, Case Histories, Plenum Press, New York, 1998.
85. S. Venkatesh and R. A. Lipper. Role of the development scientist in compound lead selection and optimization. J. Pharm. Sci. 89: 145-154 (2000).
86. E.F. "Gene" Fiese. General pharmaceutics - the new physical pharmacy. J. Pharm. Sci. 92:1331-1342 (2003).
87. W. Curatolo. Physical chemical properties of oral drug candidates in the discovery and exploratory development settings. Pharm. Sci. Tech. Today 1:387-393 (1998).
88. P. J. Sinko. Drug selection in early development: screening for acceptable pharmacokinetic properties using combined in vitro and computational approaches. Curr. Opin. Drug Disc. Dev. 2: 42-48 (1999).
89. C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Del. Rev. 23:3-25 (1997).
90. P. H. Stahl and C. G. Wermuth (eds.). Handbook of Pharmaceutical Salts: Properties, Selection and Use, VHCA, Verlag Helvetica Chimica Acta, Zürich, and Wiley-VCH, Weinheim, 2002.